Sebastian Silva

Mr. Sebastian Silva

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LBLuis E. Boero
Luis E. Boero
VCValeria C. Castagna
Valeria C. Castagna
GTGonzalo Terreros
Gonzalo Terreros
MMMarcelo J. Moglie
Marcelo J. Moglie
SSSebastian Silva
Sebastian Silva
MGMaría Eugenia Gómez-Casati
María Eugenia Gómez-Casati
Significance: Age-related hearing loss is the most common cause of hearing loss. Here, we show that medial olivocochlear feedback mediates resistance to age-related hearing loss—presbycusis—and that this occurs via the α9α10 cholinergic nicotinic receptor complexes on outer hair cells. These findings are particularly promising because they provide a proof of principle supporting the enhancement of the medial olivocochlear system as a viable approach for prevention or treatment of age-related hearing loss. Therefore, it opens the way to the design of novel positive modulators of α9α10 nAChR receptors for clinical use in the prevention of both noise and age-related hearing loss.

Verified
Journal Article
Open access
PDF file
BCBarbara Cuadra
Barbara Cuadra
VSVeronica Silva
Veronica Silva
YHYa-Lin Huang
Ya-Lin Huang
YMYael Díaz Meli
Yael Díaz Meli
Claudio RivasClaudio Rivas
Claudio Rivas
MEMarcelo Ezquer
Marcelo Ezquer
Acute-on-chronic liver failure (ACLF) is a syndrome marked by sudden liver function decline and multiorgan failure, predominantly acute kidney injury (AKY), in patients with chronic liver disease. Unregulated inflammation is a hallmark of ACLF; however, the key drivers of ACLF are not fully understood. This study explores the therapeutic properties of human mesenchymal stem cell (MSC) secretome, particularly focusing on its enhanced anti-inflammatory and pro-regenerative properties after the in vitro preconditioning of the cells. We evaluated the efficacy of the systemic administration of MSC secretome in preventing liver failure and AKI in a rat ACLF model where chronic liver disease was induced using by the administration of porcine serum, followed by D-galN/LPS administration to induce acute failure. After ACLF induction, animals were treated with saline (ACLF group) or MSC-derived secretome (ACLF-secretome group). The study revealed that MSC-secretome administration strongly reduced liver histological damage in the ACLF group, which was correlated with higher hepatocyte proliferation, increased hepatic and systemic anti-inflammatory molecule levels, and reduced neutrophil and macrophage infiltration. Additionally, renal examination revealed that MSC-secretome treatment mitigated tubular injuries, reduced apoptosis, and downregulated injury markers. These improvements were linked to increased survival rates in the ACLF-secretome group, endorsing MSC secretomes as a promising therapy for multiorgan failure in ACLF.